Radio-DARPin Platform
Various Cancers
PreclinicalPlatform
Key Facts
About Molecular Partners
Molecular Partners AG is a pioneer in the development of DARPin (Designed Ankyrin Repeat Protein) therapeutics, an entirely new class of custom-built protein drugs designed to overcome limitations of conventional biologics. The company leverages its proprietary platform to create multi-specific, logic-gated, and radio-conjugated drug candidates, primarily targeting cancers with high unmet need. Its strategy combines in-house R&D expertise with strategic partnerships to advance a diverse pipeline, including its lead programs MP0533 for AML and MP0712 for solid tumors.
View full company profileTherapeutic Areas
Other Various Cancers Drugs
| Drug | Company | Phase |
|---|---|---|
| Retifanlimab | Eli Lilly | Phase 2/3 |
| Imfinzi (durvalumab) | AstraZeneca | Approved |
| Lynparza (olaparib) | Merck | Commercial |
| Oncology Portfolio | Pfizer | Phase 1-3 |
| PD-1 Inhibitor | Akeso | Phase 2/3 |
| Mitoxantrone Liposome | CSPC Pharmaceutical Group Limited | Phase 3 |
| Biosimilar Bevacizumab | Cipla | Commercial |
| Tazverik (tazemetostat) | Eisai | Commercial |
| Oncology Generics | Aurobindo Pharma | Commercial |
| Opdivo (nivolumab) | Ono Pharmaceutical | Approved |
| Oncology APIs (e.g., Sorafenib, Lenalidomide) | Laurus Labs | Commercial/Filed |
| Tumor Marker Portfolio (PSA, CA125, etc.) | H.U. Group Holdings | Commercial |